Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
Clinical trial NCT02159365 · COMPLETED
Trial details
- NCT number
- NCT02159365
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-03-08
- Primary completion
- 2016-06-30
- Enrollment
- 84
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.